Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Rudick

Showing results (31-40 of 188) with videos related to

Pageof 19
Sort By:
Expert Opinion on Biological Therapy|September 9, 2008
LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidenceRichard A Rudick, Sha Mi, Alfred W Sandrock
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 24, 2013
Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project planRichard A Rudick, Nicholas Larocca, Lynn D Hudson, et al.
The Lancet. Neurology|October 22, 2011
Oral treatment for multiple sclerosisJoep Killestein, Richard A Rudick, Chris H Polman
Neurology|August 1, 1987
Free light chains in multiple sclerosis and infections of the CNSC DeCarli, M A Menegus, R A Rudick
Cleveland Clinic Journal of Medicine|January 1, 1992
Experimental therapies for multiple sclerosis: current statusD E Goodkin, R M Ransohoff, R A Rudick
Cleveland Clinic Journal of Medicine|May 1, 1992
Pharmacotherapy of multiple sclerosis: current statusR A Rudick, D E Goodkin, R M Ransohoff
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 1, 2007
Optimal reference population for the multiple sclerosis functional compositeR J Fox, J-C Lee, R A Rudick
Histochemistry|January 1, 1984
Preparation of monoclonal antibody-ferritin conjugates of high specific activityR A Rudick, E K Bloechl, D W Knutson
Archives of Neurology|September 1, 1985
Multiple sclerosis. Cerebrospinal fluid immune complexes that bind C1qR A Rudick, J M Bidlack, D W Knutson
The New England Journal of Medicine|June 6, 1985
Treatment of pathologic laughing and weeping with amitriptylineR B Schiffer, R M Herndon, R A Rudick
Pageof 19

Showing results (31-40 of 188) with videos related to

Sort By:
Pageof 19
Expert Opinion on Biological Therapy|September 9, 2008
LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidenceRichard A Rudick, Sha Mi, Alfred W Sandrock
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 24, 2013
Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project planRichard A Rudick, Nicholas Larocca, Lynn D Hudson, et al.
The Lancet. Neurology|October 22, 2011
Oral treatment for multiple sclerosisJoep Killestein, Richard A Rudick, Chris H Polman
Neurology|August 1, 1987
Free light chains in multiple sclerosis and infections of the CNSC DeCarli, M A Menegus, R A Rudick
Cleveland Clinic Journal of Medicine|January 1, 1992
Experimental therapies for multiple sclerosis: current statusD E Goodkin, R M Ransohoff, R A Rudick
Cleveland Clinic Journal of Medicine|May 1, 1992
Pharmacotherapy of multiple sclerosis: current statusR A Rudick, D E Goodkin, R M Ransohoff
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 1, 2007
Optimal reference population for the multiple sclerosis functional compositeR J Fox, J-C Lee, R A Rudick
Histochemistry|January 1, 1984
Preparation of monoclonal antibody-ferritin conjugates of high specific activityR A Rudick, E K Bloechl, D W Knutson
Archives of Neurology|September 1, 1985
Multiple sclerosis. Cerebrospinal fluid immune complexes that bind C1qR A Rudick, J M Bidlack, D W Knutson
The New England Journal of Medicine|June 6, 1985
Treatment of pathologic laughing and weeping with amitriptylineR B Schiffer, R M Herndon, R A Rudick
Pageof 19